Glaxo profits fall amid Avandia blow

Drugs giant GlaxoSmithKline today reported a £147m (€165.5m) hit after writing off stocks of its controversial diabetes drug Avandia.
European regulators last month suspended Avandia and further strict restrictions were placed on its US sales following evidence linking the treatment to an increased risk of heart attack.